Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis
Steen M Rønborg,1 Ulrik G Svendsen,2 Jesper S Micheelsen,3 Lars Ytte,4 Jakob N Andreasen,5 Lars Ehlers61The Pulmonology and Allergy Clinic of Copenhagen, Copenhagen, 2Bispebjerg Hospital, Copenhagen, 3Private ENT practice, Aalborg, 4General Practice Aalborg, 5ALK, Hørsh...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2012-09-01
|
| Series: | ClinicoEconomics and Outcomes Research |
| Online Access: | http://www.dovepress.com/budget-impact-analysis-of-two-immunotherapy-products-for-treatment-of--a10965 |
| _version_ | 1818557798175211520 |
|---|---|
| author | Rønborg SM Svendsen UG Micheelsen JS Ytte L Andreasen JN Ehlers L |
| author_facet | Rønborg SM Svendsen UG Micheelsen JS Ytte L Andreasen JN Ehlers L |
| author_sort | Rønborg SM |
| collection | DOAJ |
| description | Steen M Rønborg,1 Ulrik G Svendsen,2 Jesper S Micheelsen,3 Lars Ytte,4 Jakob N Andreasen,5 Lars Ehlers61The Pulmonology and Allergy Clinic of Copenhagen, Copenhagen, 2Bispebjerg Hospital, Copenhagen, 3Private ENT practice, Aalborg, 4General Practice Aalborg, 5ALK, Hørsholm, 6Aalborg University, Aalborg, DenmarkBackground: Grass pollen-induced allergic rhinoconjunctivitis constitutes a large burden for society. Up to 20% of European and United States (US) populations suffer from respiratory allergies, including grass pollen-induced allergic rhinoconjunctivitis. The majority of patients are treated with symptomatic medications; however, a large proportion remains uncontrolled despite use of such treatments. Specific immunotherapy is the only treatment documented to target the underlying cause of the disease, leading to a sustained effect after completion of treatment. The aim of this study was to compare the economic consequences of treating patients suffering from allergic rhinoconjunctivitis with either a grass allergy immunotherapy tablet (AIT) or subcutaneous immunotherapy (SCIT).Methods: A budget impact analysis was applied comparing SQ-standardized grass AIT (Grazax®; Phleum pratense, 75,000 SQ-T/2,800 BAU; ALK, Denmark) with SCIT (Alutard®; P. pratense, 100,000 SQ-U/mL; ALK, Denmark). Budget impact analysis included health care utilization measured in physical units based on systematic literature reviews, guidelines, and expert opinions, as well as valuation in unit costs based on drug tariffs, physician fees, and wage statistics. Budget impact analysis was conducted from a Danish health care perspective.Results: Treating patients suffering from allergic rhinoconjunctivitis with grass AIT instead of grass SCIT resulted in a total reduction in treatment costs of €1291 per patient during a treatment course. This cost saving implies that approximately 40% more patients could be treated with grass AIT per year without influencing the cost of treatment.Conclusion: Budget impact analysis showed that grass AIT is a cost-saving alternative to SCIT when treating patients with grass pollen-induced allergic rhinoconjunctivitis.Keywords: grass pollen, allergic rhinoconjunctivitis, allergy immunotherapy tablet, subcutaneous immunotherapy, health economics, budget impact analysis |
| first_indexed | 2024-12-14T00:04:19Z |
| format | Article |
| id | doaj.art-92fa2eb342294cd187711b8c6da33959 |
| institution | Directory Open Access Journal |
| issn | 1178-6981 |
| language | English |
| last_indexed | 2024-12-14T00:04:19Z |
| publishDate | 2012-09-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | ClinicoEconomics and Outcomes Research |
| spelling | doaj.art-92fa2eb342294cd187711b8c6da339592022-12-21T23:26:08ZengDove Medical PressClinicoEconomics and Outcomes Research1178-69812012-09-012012default253260Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitisRønborg SMSvendsen UGMicheelsen JSYtte LAndreasen JNEhlers LSteen M Rønborg,1 Ulrik G Svendsen,2 Jesper S Micheelsen,3 Lars Ytte,4 Jakob N Andreasen,5 Lars Ehlers61The Pulmonology and Allergy Clinic of Copenhagen, Copenhagen, 2Bispebjerg Hospital, Copenhagen, 3Private ENT practice, Aalborg, 4General Practice Aalborg, 5ALK, Hørsholm, 6Aalborg University, Aalborg, DenmarkBackground: Grass pollen-induced allergic rhinoconjunctivitis constitutes a large burden for society. Up to 20% of European and United States (US) populations suffer from respiratory allergies, including grass pollen-induced allergic rhinoconjunctivitis. The majority of patients are treated with symptomatic medications; however, a large proportion remains uncontrolled despite use of such treatments. Specific immunotherapy is the only treatment documented to target the underlying cause of the disease, leading to a sustained effect after completion of treatment. The aim of this study was to compare the economic consequences of treating patients suffering from allergic rhinoconjunctivitis with either a grass allergy immunotherapy tablet (AIT) or subcutaneous immunotherapy (SCIT).Methods: A budget impact analysis was applied comparing SQ-standardized grass AIT (Grazax®; Phleum pratense, 75,000 SQ-T/2,800 BAU; ALK, Denmark) with SCIT (Alutard®; P. pratense, 100,000 SQ-U/mL; ALK, Denmark). Budget impact analysis included health care utilization measured in physical units based on systematic literature reviews, guidelines, and expert opinions, as well as valuation in unit costs based on drug tariffs, physician fees, and wage statistics. Budget impact analysis was conducted from a Danish health care perspective.Results: Treating patients suffering from allergic rhinoconjunctivitis with grass AIT instead of grass SCIT resulted in a total reduction in treatment costs of €1291 per patient during a treatment course. This cost saving implies that approximately 40% more patients could be treated with grass AIT per year without influencing the cost of treatment.Conclusion: Budget impact analysis showed that grass AIT is a cost-saving alternative to SCIT when treating patients with grass pollen-induced allergic rhinoconjunctivitis.Keywords: grass pollen, allergic rhinoconjunctivitis, allergy immunotherapy tablet, subcutaneous immunotherapy, health economics, budget impact analysishttp://www.dovepress.com/budget-impact-analysis-of-two-immunotherapy-products-for-treatment-of--a10965 |
| spellingShingle | Rønborg SM Svendsen UG Micheelsen JS Ytte L Andreasen JN Ehlers L Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis ClinicoEconomics and Outcomes Research |
| title | Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis |
| title_full | Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis |
| title_fullStr | Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis |
| title_full_unstemmed | Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis |
| title_short | Budget impact analysis of two immunotherapy products for treatment of grass pollen-induced allergic rhinoconjunctivitis |
| title_sort | budget impact analysis of two immunotherapy products for treatment of grass pollen induced allergic rhinoconjunctivitis |
| url | http://www.dovepress.com/budget-impact-analysis-of-two-immunotherapy-products-for-treatment-of--a10965 |
| work_keys_str_mv | AT ramposlashnborgsm budgetimpactanalysisoftwoimmunotherapyproductsfortreatmentofgrasspolleninducedallergicrhinoconjunctivitis AT svendsenug budgetimpactanalysisoftwoimmunotherapyproductsfortreatmentofgrasspolleninducedallergicrhinoconjunctivitis AT micheelsenjs budgetimpactanalysisoftwoimmunotherapyproductsfortreatmentofgrasspolleninducedallergicrhinoconjunctivitis AT yttel budgetimpactanalysisoftwoimmunotherapyproductsfortreatmentofgrasspolleninducedallergicrhinoconjunctivitis AT andreasenjn budgetimpactanalysisoftwoimmunotherapyproductsfortreatmentofgrasspolleninducedallergicrhinoconjunctivitis AT ehlersl budgetimpactanalysisoftwoimmunotherapyproductsfortreatmentofgrasspolleninducedallergicrhinoconjunctivitis |